ATR and female reproductive organ cancer: The ataxia telangiectasia and Rad3-related (ATR) inhibitors, DNA-dependent protein kinase (DNA-PK) inhibitors, WEE1 inhibitors, and checkpoint kinase 1/2 (CHK1/2) inhibitors have shown promising clinical results recently, and a number of ongoing trials are focusing on gynecologic cancers [25,125] (Table 2 and Table 3).